Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

News argenx SE Nasdaq

Equities

ARGX

US04016X1019

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
430 USD -3.35% Intraday chart for argenx SE +9.02% +13.04%
06-26 HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating MT
06-24 Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating
MT
Argenx : argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
PU
Argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
GL
Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained
MT
Scotiabank Raises Argenx's Price Target to $416 From $408, Sector Perform Rating Maintained
MT
Goldman Sachs Raises Argenx's Price Target to $506 From $484, Buy Rating Maintained
MT
Citigroup Raises Argenx's Price Target to $512 From $463, Buy Rating Maintained
MT
European shares start the week higher on autos, banks
RE
Argenx Shares Rise Following Vyvgart Hytrulo Approval
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...
Our Logo
BofA Securities Raises Argenx Price Target to $607 From $535, Maintains Buy Rating
MT
Stifel Raises Argenx Price Target to $500 From $485, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Advance Premarket Monday
MT
Piper Sandler Adjusts argenx Price Target to $535 From $522, Maintains Overweight Rating
MT
Wells Fargo Adjusts argenx Price Target to $542 From $478, Maintains Overweight Rating
MT
Evercore ISI Raises Price Target on argenx to $478 From $437, Keeps Outperform Rating
MT
Argenx Says FDA Approved Vyvgart Hytrulo for Treatment of Neuromuscular Disorder
MT
European shares start week on bright footing on autos, banks' boost
RE
Argenx : argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. ARGX Stock
  5. News argenx SE